



DATASHEET

PrecisION™

hKv4.3/hKChIP1- CHO

Recombinant Cell Line

CATALOG # CYL3027

REVISION # M05

ORDERING INFORMATION AND TECHNICAL SERVICES

Millipore (UK) Ltd
6-7 Technopark
Cambridge CB5 8PB
UK

Tel: +44 (0) 1223 508191

Fax: +44 (0) 1223 508198


CUSTOMER SERVICES

UK: 0800 0190 333


US: 800 437 7500




GPCR



Ion Channels



Kinase /
Phosphatase



Safety & Toxicity
Profiling

Product description:

Recombinant CHO-K1 cell line expressing human Kv4.3 and human KChIP1 (accession numbers NM_004980 and NM_014592 respectively).

Format:

2 x 1 ml aliquots containing 1.04×10^6 cells/ml in 10% DMSO at passage 8.

Mycoplasma Testing:

The cell line has been screened by the PCR VenorGem kit (Minerva Biolabs) to confirm the absence of Mycoplasma species.

Functional Validation:

CHO-K1 cells expressing hKv4.3 and hKChIP1 were characterized in terms of their pharmacological and biophysical properties using whole-cell patch clamp techniques and IonWorks™ HT.

Co-expression of both subunits is strongly supported by the increase in the mean peak currents with respect to expression of Kv4.3 alone (from 9 to 22 nA as recorded using whole-cell patch clamp techniques and from 2.5 to 4.2 nA as measured with IonWorks™ HT).

In addition cells expressing both subunits displayed a more rapid recovery from inactivation (141 ms) with respect to cells expressing just hKv4.3 (1319 ms).

The hKv4.3/hKChIP1 current was inhibited by the antagonists quinidine and flecainide with IC₅₀ values of 20 μM and 58 μM respectively.

Recommended culture Conditions:

Recommended culture conditions and standard operating procedure are provided with the product.

Licensing Statements

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242, USA.

The bovine growth hormone (bgh) polyadenylation signal and its use in the expression of recombinant proteins is covered by claims listed in U.S. Patent No. 5,122,458, EU Patent No. 0 173 552 and Japanese Patent No. 1955752 (collectively "CLAIMED DNA and/or CLAIMED CELLS") owned and licensed to Millipore (formerly Upstate Biotechnology Inc.) by Research Corporation Technologies, Inc., 101 North Wilmot Road, Suite 600, Tucson, AZ 85711-3335 ("RCT").

Use of this technology is restricted to research purposes only. The purchased/licensed cell line and all bacteria, phages and plasmids derived from this cell line, in whole or in part, and all proteins expressed from the cell line shall be used for research uses only. "Research purposes" means uses directed to the identification of useful recombinant proteins and the investigation of the recombinant expression of proteins. In no event shall research use include any of the following: any use in humans of a CLAIMED DNA or CLAIMED CELL; any use in human or protein expression or other substance expressed or made at any stage of its production that use the CLAIMED DNA or a CLAIMED CELL; or any use in which a CLAIMED DNA or CLAIMED CELL would be sold or transferred to a third party. No license, other than research use, is expressed or implied by the purchase/license of the cell line. By accepting or using Millipore's cell line product, you agree to be bound for the following use/license restrictions:

This product enables the user which purchased/licensed it to use the cDNA construct for research purposes only, and additional restrictions apply to commercial uses of the cell line. Such commercial uses, include uses such as resale, bulk preparation of proteins encoding the cDNA, application of the product with transgenic animals or human experiments, or use in screening or drug development. All commercial uses require a separate written license from Millipore Corporation and may require additional licenses from RCT, whose contact is Dr. Jennifer Tonzello, phone, +001 520-748-4441.

Provided under license from Wyeth Pharmaceuticals, Collegeville, PA 19426, USA.

This product is covered by the U.S. Patent Nos. 6,361,971, 6,369,197, 6,395,477, 6,689,581, and the U.S. Application Nos. 09/400,492, 09/670,756, 09/703,094, 10/062,879, 10/106,989, 10/118,590.

Product shall be used for Research Purposes only. Research Purposes means screening activities related to drug discovery research, and excludes use of the Product for any human or animal therapeutic or diagnostic application.

IonWorks™ HT is a trademark of Molecular Devices Corporation

Electrophysiological Properties of the hKv4.3/hKChIP1 current.

The Kv4.3 channel is a voltage-gated potassium channel with A-type potassium currents (Gutman *et al.*, 2005). The channel is distributed in the heart, brain and smooth muscle (Serodio *et al.*, 1994; Serodio *et al.*, 1996; Serodio and Rudy, 1998; Gutman *et al.*, 2005). The Kv4 channels contribute to shape the repolarisation of the action potential in the heart (Nerbonne, 2000; Oudit *et al.*, 2001) and in neurones they contribute to the control of the frequency of slow repetitive firing and prevent back-propagation of action potentials (Hoffman *et al.*, 1997; Shibata *et al.*, 2000).

The Kv Channel Interacting Proteins (KChIP) interact specifically with Kv4 channels, upregulating current expression and modulating aspects of channel inactivation (An *et al.*, 2000). KChIP1 increases the current densities of Kv4.3, accelerates the inactivation time course, accelerates the recovery from inactivation and shifts steady-state inactivation to more depolarized potentials (An *et al.*, 2000; Beck *et al.*, 2002; Holmqvist *et al.*, 2002).

Conventional Whole-Cell Patch Clamp Electrophysiology.

Current/Voltage Relationship:

Figures 1 and 2 show potassium currents, evoked by 4 s voltage steps from -80 mV to $+50$ mV in 10 mV increments, applied from a holding potential of -80 mV in cells expressing hKv4.3/hKChIP1 and hKv4.3 alone respectively. The current/voltage relationships are very similar with activation of the current occurring at voltages more positive than $-40/-30$ mV in both cell lines. This finding is in agreement with published findings (Beck *et al.*, 2002; Holmqvist *et al.*, 2002; Patel *et al.*, 2004). However, the average current size in the cells expressing hKv4.3/hKChIP1 (22.4 nA) was over twice the size that in the hKv4.3 line (9.1 nA) a result also described by both An *et al.*, 2000 and Holmqvist *et al.*, 2002 co-expressing Kv4.3 and KChIP1 in *Xenopus* oocytes.

Figure 1. Typical hKv4.3/hKChIP1 currents (upper panel) elicited by depolarising voltage pulses from -80 mV to $+50$ mV in 10 mV increments every 4 s from a holding potential of -80 mV. Scale bars represent 100 ms (x-axis) and 5 nA (y-axis).






Figure 2. Current-Voltage (I/V) Relationships.

A. hKv4.3/hKChIP1: Peak current amplitudes were normalized to the current amplitude obtained at +50 mV. The mean current at +50 mV was 22.4 ± 6.5 nA (Mean \pm SEM, n= 6).

B. hKv4.3: Peak current amplitudes were normalized to the current amplitude obtained at +50 mV. The mean current at +50 mV was 9.1 ± 4.7 nA (Mean \pm SEM, n= 7).


A**B**

Recovery from Inactivation:

Whilst the I/V relationship is unaffected, the recovery from inactivation is markedly altered by co-expression of the hKChIP1 subunit. **Figure 3A** shows the rapid recovery from inactivation of currents in a cell expressing hKv4.3/hKChIP1. Compare this to the slower recovery when a cell expresses hK4.3 alone (**Figure 3B**). Mean data from several cells is shown in graphical form in **Figure 4**. The value for recovery from inactivation (τ) were 319 ± 29 ms (n=7) and 141 ± 33 ms (n=4) for hKv4.3 and hKv4.3/hKChIP1 respectively (mean \pm SEM). Similarly, An *et al.*, 2000, Holmqvist *et al.*, 2002 and Beck *et al.*, 2002 found that co-expression of the subunit speeds up the recovery from inactivation ($\tau=120$ -327 ms when expressing hKv4.3 alone and 34.5-63 ms when expressing hKv4.3/hKChIP1, mean \pm SEM, all data from *Xenopus* oocytes).

Figure 3.

A. hKv4.3/hKChIP1: Currents evoked by stepping from holding potential of -80 mV to 50 mV for 1 s for the 1st pulse and for 100 ms for the second pulse. Scale bars represent 500 ms and 5 nA. Red line is single exponential fit to peak of 2nd pulse peak currents. Second pulses after a interval of $5, 10, 20, 40, 80, 160, 320, 640, 1280, 2560$ ms.



B. hKv4.3: Currents evoked as above. Scale bars represent 500 ms and 1 nA. Red line is single exponential fit to peak of 2nd pulse peak currents. Second pulses after a interval of $5, 10, 20, 40, 80, 160, 320, 640, 1280, 2560$ ms.





Figure 4. Recovery of currents from inactivation.

Normalised peak currents (y-axis) are plotted against the recovery time (x-axis). hKv4.3 alone (black) and hKv4.3 coexpressed with hKChIP1 (red). The values for recovery from inactivation (τ) were 319 ± 29 ms (n=7) and 141 ± 33 ms (n=4) for hKv4.3 and hKv4.3/hKChIP1 respectively (mean \pm SEM).




IonWorks™ HT Electrophysiology.

Comparison of peak current amplitudes in hKv4.3/hKChIP1-CHO K1 and hKv4.3 -CHO K1 cell lines: Both cell lines were studied using the same double-pulse voltage protocol shown in **Figure 5A** (red trace). A typical current response elicited by this protocol is shown in magenta. The results of this comparison are shown in a histogram in **Figure 5B**. The co-expression of hKv4.3 with hKChIP1 increased the mean peak current amplitude from 2.5 ± 0.12 nA (n=156) to 4.2 ± 0.25 (n=140) (mean \pm SEM). These values reflect the increase in mean current values, obtained by conventional whole-cell patch clamp electrophysiology, from 9.1 nA to 22.4 nA in cells expressing hKv4.3 and hKv4.3/hKChIP1 respectively.


Figure 5.

- A. Current responses and voltage protocol.
- B. Current amplitude distributions.

A




B



Recovery from Inactivation:


The recovery of the current from inactivation was also studied on IonWorks™ HT using the same double pulse voltage protocol as before and shown again in **Figure 6** (red trace). In order to quantify the difference in the degree of recovery from inactivation between the two cell lines, the following metric (Peak Amp1 / Peak Amp2) was applied to the currents obtained by pulses 1 and 2 (**Figure 6**).

Figure 6.



In agreement with the data from the conventional whole-cell patch clamp experiments, the currents in the hKv4.3/hKChIP1-CHO K1 cell line display a more rapid recovery from inactivation than the hKv4.3-CHO K1 currents and therefore have a ratio closer to 1.


Figure 7.



Pharmacology – Quinidine and Flecainide:

The antagonists quinidine and flecainide are both known antagonists of Kv4.3 currents. In these studies, the pre-compound and post-compound currents elicited by the double pulse protocol were recorded and the post-/pre-compound ratio plotted against antagonist concentration (**Figure 8**).

Figure 8. Dose-response curves for the reduction in post-/pre-compound ratio by the antagonists quinidine and flecainide.




Stability of hKv4.3/hKChIP1-CHO K1 Cell Line:

The hKv4.3/hKChIP1-CHO K1 cell line has stable expression for >90 passages.


Figure 9. Stability of expression over passage.

The upper panel shows the percentage of cells expressing a mean peak current >500 pA at cell passages 34, 38, 52, 62, and 90. The lower panel shows the mean current amplitude (mean \pm SEM, red circles) and the number of these cells (numbers above red circles).




Vectors:

hKv4.3-pcDNA3.1/zeo(+)



hKChIP1-pWE2



hKv4.3 Sequence:

The sequence of the cDNA used to make this cell line contains two silent mutations and two coding mutations (GCC-ACC (Ala-Thr) and GCC-GTC (Ala-Val)) with respect to the accession number NM_004980.

hKChIP1 Sequence (Accession Number NM_014592):**References**

An, W.F., Bowlby, M.R., Betty, M., Cao, J., Ling, H.P., Mendoza, G., Hinson, J.W., Mattsson, K.I., Strassle, B.W., Trimmer, J.S. and Rhodes, K.J. (2000). Modulation of A-type potassium channels by a family of calcium sensors. *Nature* **403**, 553-556.

Beck, E.J., Bowlby, M., An, W.F., Rhodes, K.J. and Covarrubias, M. (2002). Remodelling inactivation gating of Kv4 channels by KChIP1, a small-molecular-weight calcium-binding protein. *J Physiol* **538**, 691-706.

Gutman, G.A., Chandy, K.G., Grissmer, S., Lazdunski, M., McKinnon, D., Pardo, L.A., Robertson, G.A., Rudy, B., Sanguinetti, M.C., Stuhmer, W, and Wang, X. (2005). International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. *Pharmacol Rev* **57**, 473-508.

Hoffman, D.A., Magee, J.C., Colbert, C.M. and Johnston, D. (1997). K⁺ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. *Nature* **387**, 869-875.

Holmqvist, M.H., Cao, J., Hernandez-Pineda, R., Jacobson, M.D., Carroll, K.I., Sung, M.A., Betty, M., Ge, P., Gilbride, K.J., Brown, M.E., Jurman, M.E., Lawson, D., Silos-Santiago, I., Xie, Y., Covarrubias, M., Rhodes, K.J., Distefano, P.S. and An, W.F. (2002). Elimination of fast inactivation in Kv4 A-type potassium channels by an auxiliary subunit domain. *Proc Natl Acad Sci U S A* **99**, 1035-1040.

Nerbonne, J.M.. (2000). Molecular basis of functional voltage-gated K⁺ channel diversity in the mammalian myocardium. *J Physiol (Lond)* **525**, 285-298.

Oudit, G.Y., Kassiri, Z., Sah, R., Ramirez, R.J., Zobel, C. and Backx, P.H. (2001). The molecular physiology of the cardiac transient outward potassium current (I_{to}) in normal and diseased myocardium. *J Mol Cell Cardiol* **33**, 851-872.

Patel, S.P., Parai, R., Parai, R. and Campbell, D.L. (2004). Regulation of Kv4.3 voltage-dependent gating kinetics by KChIP2 isoforms. *J Physiol* **557**, 19-41.

Schroeder, K., Neagle, B., Trezise D.J. and Worley, J. (2003) IonWorks™ HT: a new high-throughput electrophysiology measurement platform. *J. Biomol Screen* **8 (1)**: 50-64.

Serodio, P., Kentros, C. and Rudy, B. (1994). Identification of molecular components of A-type channels activating at subthreshold potentials. *J Neurophysiol* **72**, 1516-1529.

Serodio, P. and Rudy, B. (1998). Differential expression of Kv4 K⁺ channel subunits mediating subthreshold transient K⁺ (A-type) currents in rat brain. *J Neurophysiol* **79**, 1081-1091.

Serodio, P., Vega-Saenz de Miera, E. and Rudy, B. (1996). Cloning of a novel component of A-type K⁺ channels operating at subthreshold potentials with unique expression in heart and brain. *J Neurophysiol* **75**, 2174-2179.

Shibata, R., Nakahira, K., Shibasaki, K., Wakazono, Y., Imoto, K. and Ikenaka, K. (2000). A-type K⁺ current mediated by the Kv4 channel regulates the generation of action potential in developing cerebellar granule cells. *J Neurosci* **20**, 4145-4155.